1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Shenzhen Neptunus Bioengineering Co., Ltd.

Shenzhen Neptunus Bioengineering Co., Ltd.

000078.SZ
Shenzhen Neptunus Bioengineering Co., Ltd.CN flagShenzhen Stock Exchange
1.98
CNY
+0.18
- -
5.21BMarket Cap
Shenzhen Neptunus Bioengineering Co., Ltd.
000078.SZ
(Shenzhen Stock Exchange)

Recent

price

1.98

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.45
3.25
3.93
4.49
5.36
15.19
6.13
9.42
14.51
15.68
15.26
15.62
14.39
13.84
11.52
10.14
10.62
Revenue per Share
0.03
0.03
0.04
0.07
0.01
0.65
0.19
0.24
0.17
0.08
-0.11
0.04
-0.39
-0.64
-0.45
-0.21
-0.46
Basic EPS, GAAP
-0.04
-0.18
-0.15
-0.23
-0.19
-0.11
-0.8
-1.02
-0.51
0.79
0.57
0.28
-0.06
-0.2
-0.02
-0.01
-0.04
Free Cash Flow per Basic Share
0.06
0.07
0.09
0.09
0.12
0.39
0.09
0.06
0.41
0.51
0.29
0.22
0.25
0.21
0.19
0.2
0.17
Dividend per Share
-0.22
-0.18
-0.15
-0.02
-0.01
0.65
1.26
1.22
1.38
1.49
1.39
1.42
1.03
0.39
-0.11
-0.33
-0.1
Book Value per Share
0.42
0.45
0.48
0.87
0.78
2.33
2.27
0.95
1.09
1.56
1.76
1.69
1.46
1.1
0.76
0.57
0.77
Tangible Book Value per Share
1,632
1,631
1,632
1,780
1,830
732
2,221
2,648
2,646
2,646
2,623
2,628
2,630
2,631
2,631
2,631
2,635
Basic Weighted Avg Shares
3,999
5,305
6,418
7,993
9,802
11,118
13,606
24,940
38,381
41,493
40,022
41,054
37,835
36,419
30,317
26,668
27,997
Sales/Revenue/Turnover
4.16
4.28
3.59
3.41
3.73
4.39
5.97
6.43
5.1
5.58
4.57
3.83
2.67
2.43
1.75
2.13
1.17
Operating Margin (%)
53
53
61
70
87
80
75
103
131
152
194
269
276
284
245
215
- -
Depreciation Expense
47
53
59
117
24
475
418
639
448
206
-289
93
-1,027
-1,690
-1,193
-563
-1,207
Net Income, GAAP
48.68
38.1
6.57
34.17
46.64
17.6
23.7
28.78
30.82
41.25
115.44
55.26
- -
- -
- -
- -
193.72
Effective Tax Rate (%)
1.17
0.99
0.92
1.46
0.24
4.27
3.08
2.56
1.17
0.5
-0.72
0.23
-2.71
-4.64
-3.94
-2.11
-4.31
Profit Margin (%)
-223
-15
-73
509
154
740
3,696
2,350
3,058
2,742
1,677
1,855
1,831
1,081
256
36
545
Working Capital
62
- -
- -
- -
- -
- -
24
1,703
3,374
1,359
357
377
400
320
330
435
405
LT Debt
903
971
1,057
1,888
1,783
2,143
5,878
6,470
7,158
7,851
7,490
7,308
6,112
4,217
2,844
2,177
2,850
Total Equity
4.21
5.74
7.53
4.85
4.48
8.47
9.34
10.81
8.13
6.54
-1.3
3.33
- -
- -
- -
- -
- -
Return on Invested Capital (%)
7.95
8
8.7
4.47
1.99
19.11
10.71
8.92
5.72
3.36
-3.56
1.7
- -
- -
- -
- -
89.74
Return on Capital (%)
- -
- -
- -
- -
- -
- -
25.63
21.27
13.02
5.43
-7.61
2.53
-31.86
-90.6
- -
- -
-92.52
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
10,245
10,046
9,899
LT Borrowings
230
356
320
LT Finance Leases
100
94
85
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,631
2,631
2,631
Market Capitalization
6,712
6,245
6,377

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
25,835
25,757
24,936
Cash, Cash Equivalents & STI
3,582
3,399
3,187
Accounts Receivable, Net
15,319
15,367
15,148
Inventories
3,487
3,361
3,358
Total Current Liabilities
25,579
25,203
24,391
Payables & Accruals
- -
- -
- -
ST Debt
10,245
10,046
9,899
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.42%
-21.16%
-23.46%
Free Cash Flow
176.05%
-17.84%
-49.63%
Net Income, GAAP
-163.35%
-270.15%
-52.82%
Sales/Revenue/Turnover
12.64%
-7.56%
-12.04%
Total Cash Common Dividend
43.31%
-6.78%
1.29%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,088
8,544
7,921
5,765
30,317
2025
7,376
6,936
5,155
- -
26,668
2026
5,945
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
-0.45
2025
0.01
- -
- -
- -
-0.21
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
- -
- -
- -
0.19
2025
0.04
- -
- -
- -
0.2
2026
0.04
- -
- -
- -
- -
Similar Companies
Shilpa Medicare Limited (SHILPAMED.BO)
Levitee Labs Inc. (LVT.CN)
Heritage Cannabis Holdings Corp. (HERTF)
Laurus Labs Limited (LAURUSLABS.BO)
iAnthus Capital Holdings, Inc. (IAN.CN)
Shandong Xinhua Pharmaceutical Company Limited (0719.HK)
Business
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) engages in the research, development, production, and sales of Chinese patent medicines, infusion products, and western medicine preparations primarily in China; oryzanol tablets, chlorpheniramine tablets, chlorpheniramine maleate tablets, estazolam tablets, rifampicin capsules, antiviral and anti-infective drugs, cardiovascular medications, and immune regulators; drugs targeting malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, respiratory system diseases, and digestive system diseases; distribution of drugs, medical devices, and medical supplies; value-added services for hospitals, medical institutions, drug retailers, and distributors. Founded in 1989 and headquartered in Shenzhen, China, the company operates a vertically integrated model covering pharmaceutical commerce, industry, and R&D, with a focus on domestic markets supplemented by international exports to regions including Southeast Asia and Africa. Recent developments include receipt of clinical trial approval in March 2025 for NEP018 tablets, a novel small molecule kinase inhibitor for gastrointestinal tumors developed by its wholly-owned Shenzhen Neptunus Pharmaceutical Technology Research Institute Co., Ltd., alongside continued R&D investment at approximately 8.5% of revenue and termination of certain cooperation agreements with Neptunus Group and Silk Spinning Group in June 2025.